Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jonathan L Carter
Observed names:
J Carter,
Jonathan L. Carter
Institutions:
Mayo Clinic,
Mayo Clinic in Arizona
Observed institutions:
Mayo Clinic,
Mayo Clinic in Arizona
OpenAlex ID:
A5111741535
Cladribine tablets added to IFN-β in active relapsing MS
2018
·
Xavier Montalban
, Thomas P. Leist
, et al.
·
Neurology Neuroimmunology & Neuroinflammation
·
67
PDF
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
2020
·
Jacqueline Palace
, Dean M. Wingerchuk
, et al.
·
Multiple Sclerosis and Related Disorders
·
45
PDF
Cerebral enhancement in MOG antibody-associated disease
2023
·
Paul Elsbernd
, Laura Cacciaguerra
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
36
PDF
Peripheral sensory abnormalities in patients with multiple sclerosis
1992
·
Jeremy M. Shefner
, Jonathan L. Carter
, et al.
·
Muscle & Nerve
·
33
Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders
1999
·
Jeffrey A Cohen
, Jonathan L Carter
, et al.
·
Journal of Neuroimmunology
·
23
An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis
2020
·
Cristina Valencia-Sanchez
, Jonathan L. Carter
·
Expert Opinion on Pharmacotherapy
·
18
The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations
2019
·
Cristina Valencia-Sanchez
, Brent P Goodman
, et al.
·
Multiple Sclerosis Journal
·
16
Otoacoustic emissions in sudden unilateral hearing loss associated with multiple sclerosis.
1995
·
M J Cevette
, M S Robinette
, et al.
·
PubMed
·
16
Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review
2021
·
Paul M Elsbernd
, Jonathan L Carter
·
Biologics
·
10
PDF
Show more works
View as search
Works count:
9
Citation count:
264
H-index:
9
I10-index:
9
Year
Topic
Type
